Company / Cash & Equivalents
LifeStance Health Group, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$248.6M
FY2025
5-year range
$78.8M / $248.6M
FY2021-FY2025
Trend
+60.9%
vs FY2024
Sector context
#74 of 152
Health Care
What the data says
At $249M, LifeStance Health Group, Inc.'s cash & equivalents ranks #74 of 152 in the Health Care sector. Improved from $79M to $249M over the past 2 years.
Based on SEC 10-K filings.
$249M in FY2025 with a 5-year CAGR of +67.6%.
Improved from $79M to $249M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +31.8%
- 5-Year CAGR
- +67.6%
- 10-Year CAGR
- -
Sector benchmark
#74 of 152 in Health CareTop 49% of 152This company $248.6M Sector average $1.2B
▼
-78.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +67.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 60.9% year-over-year.
- Ranks #74 out of 152 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $248.6M | +60.9% |
| FY2024 | $154.6M | +96.1% |
| FY2023 | $78.8M | -27.4% |
| FY2022 | $108.6M | -26.6% |
| FY2021 | $148.0M | +686.2% |
| FY2020 | $18.8M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026